Cell engineering platform technology company MaxCyte announced the signing of a clinical and commercial licence with Sana Biotechnology on Monday.
The AIM-traded firm described Sana as a company focused on “creating and delivering” engineered cells as medicines.
Under the terms of the deal, Sana Biotechnology would obtain non-exclusive clinical and commercial rights to use MaxCyte’s ‘Flow Electroporation’ technology and ‘ExPERT’ platform.
In return, MaxCyte would be entitled to receive platform licensing fees and program-related milestone payments.
“We are delighted to support Sana’s ex vivo cell therapy programs and recognize the potential of the company’s novel hypoimmune cell platform to advance treatments for serious diseases,” said chief executive officer Doug Doerfler.
“This agreement represents an important achievement for MaxCyte as we continue to expand the use of our next-generation technology platform to support the development of innovative treatments.”
At 1151 BST, shares in MaxCyte were up 1.01% at 1,050.5p.
